Peter Niebl

Mr. Peter Niebl


Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2015 in Thrombosis Research
Verified
Journal Article
Open access
EHEva Herzog
Eva Herzog
FKFranz Kaspereit
Franz Kaspereit
WKWilfried Krege
Wilfried Krege
JMJochen Mueller-Cohrs
Jochen Mueller-Cohrs
BDBaerbel Doerr
Baerbel Doerr
GDGerhard Dickneite
Gerhard Dickneite
Rivaroxaban is an oral, selective direct factor Xa inhibitor approved for several indications in patients at risk of thrombotic events. One limitation of its clinical use is the lack of data pertaining to its reversal in situations where urgent response is critical (e.g. acute bleeding events or emergency surgery). This study assessed the effectiveness of a four-factor prothrombin complex concentrate (4F-PCC; Beriplex(®)/Kcentra(®)) for the reversal of rivaroxaban-associated bleeding in an in vivo rabbit model, and evaluated the correlations between in vitro coagulation parameters and haemostasis in vivo. Administration of single intravenous doses of rivaroxaban (150-450 μg/kg) resulted in increased and prolonged bleeding following standardised kidney incision. Pre-incision treatment with 4F-PCC (25-100 IU/kg) resulted in a dose-dependent reversal of rivaroxaban (150 and 300 μg/kg)-associated increases in time to haemostasis and blood loss; no reversal was seen at the highest rivaroxaban dose (450 μg/kg). Of the in vitro biomarkers tested, thrombin generation and whole-blood clotting time correlated well with in vivo measures of 4F-PCC-mediated effects. Thrombin generation was highly reagent-dependent, with the assay initiated using the phospholipid-only reagent being the most predictive of effective haemostasis in vivo. In summary, in a rabbit model of acute bleeding, treatment with 4F-PCC reduced bleeding to control levels following rivaroxaban 150 μg/kg and 300 μg/kg administration.

7 December 2025 in Animals
Verified
Journal Article
Open access
PDF file
ASArman Shamsi
Arman Shamsi
PNPeter Niebl
Peter Niebl
AKAnnika Kalina
Annika Kalina
Stephanie KrämerStephanie Krämer
Stephanie Krämer
MNMarc Nolte
Marc Nolte
STSimone Tangermann
Simone Tangermann
The standardization of husbandry in animal studies for drug development aims to minimize variability and enhance inter-laboratory comparability. Rats are a commonly used species in such studies. This standardization yields housing conditions that do not reflect the natural environment of rats, raising animal welfare concerns and prompting discussions about whether such conditions might also influence physiological or behavioral outcomes, thereby potentially affecting the translatability of study results. In this study, we compared a two-level, enriched colony cage housing groups of ten Sprague-Dawley rats with conventional pair-housed Type IV cages over 28 days, asking whether social and physical complexity alters parameters relevant to early drug development and safety assessment. These included body weight, food and water intake, behavior (open field, elevated plus maze), hematology, clinical chemistry, blood gases, gross pathology, organ weights, histopathology, and IgG levels. Differences in key measures between housing conditions were minimal: Hematology showed time-restricted shifts. On study day 28, immunoglobulin G concentrations were higher in conventionally housed animals, though values were comparable and within the normal range. Behavioral tests revealed notable but limited differences between housing conditions, mainly involving locomotor activity. Clinical chemistry and blood gases were largely unchanged. Body weight, food and water intake, and pathology parameters were comparable. Together, these findings demonstrate that enriched colony housing can be implemented as a refinement strategy without compromising the integrity of key study endpoints relevant to early drug development and safety assessment.